JAK2Mutations in Polycythemia Vera — Molecular Mechanisms and Clinical Applications
- 1 February 2007
- journal article
- editorial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 356 (5) , 444-445
- https://doi.org/10.1056/nejmp068293
Abstract
Janus kinase 2 (JAK2) is a cytoplasmic tyrosine kinase that transduces signals, especially those triggered by hematopoietic growth factors such as erythropoietin, in normal and neoplastic cells. In March and April 2005, four groups of investigators reported finding an acquired JAK2 mutation (termed JAK2 V617F) in association with polycythemia vera and related myeloproliferative disorders.1 These seminal reports have already been cited many times, and JAK2 is now a target for the development of new treatments for the myeloproliferative disorders. JAK2 V617F is detectable in more than 95% of patients who have polycythemia vera, as defined according to conventional criteria. The . . .Keywords
This publication has 6 references indexed in Scilit:
- JAK2Exon 12 Mutations in Polycythemia Vera and Idiopathic ErythrocytosisNew England Journal of Medicine, 2007
- MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid MetaplasiaPLoS Medicine, 2006
- Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disordersBlood, 2005
- JAK2 in Myeloproliferative Disorders Is Not Just Another KinaseCell Cycle, 2005
- A Gain-of-Function Mutation ofJAK2in Myeloproliferative DisordersNew England Journal of Medicine, 2005
- A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraNature, 2005